Please find enclosed financial result for the quarter ended 30th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tejnaksh Healthcare reported a weak set of numbers for Q2 FY26, with consolidated revenue from operations falling to Rs. 297.81 lakhs from Rs. 336.86 lakhs a year ago, an ~12% YoY decline. H1 FY26 revenue dropped ~13.5% to Rs. 561.78 lakhs versus Rs. 649.25 lakhs in H1 FY25. Profit after tax on a consolidated basis nearly halved to Rs. 33.15 lakhs in Q2 FY26 from Rs. 65.31 lakhs in Q2 FY25, while H1 FY26 PAT fell ~55% to Rs. 54.52 lakhs. Standalone PAT for Q2 FY26 was Rs. 31.04 lakhs (vs Rs. 56.30 lakhs), with EPS of Rs. 0.15 for the quarter. The limited review report from Maheshwari & Co. is clean with no modifications, and the company continues to operate debt-light with a consolidated net cash position.
The double-digit decline in both revenue and profit YoY signals continued operational pressure on the hospital business, and shareholders should expect a negative near-term reaction. However, the clean audit, single-segment healthcare focus, and negligible debt limit downside risk.